| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
|
N Engl J Med
|
2009
|
10.54
|
|
2
|
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
|
Nature
|
2012
|
9.89
|
|
3
|
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
|
Blood
|
2008
|
5.49
|
|
4
|
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
|
N Engl J Med
|
2014
|
5.37
|
|
5
|
JAK mutations in high-risk childhood acute lymphoblastic leukemia.
|
Proc Natl Acad Sci U S A
|
2009
|
4.98
|
|
6
|
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.
|
Nat Genet
|
2011
|
4.93
|
|
7
|
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.
|
Cancer Cell
|
2012
|
4.41
|
|
8
|
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.
|
Nat Genet
|
2009
|
4.35
|
|
9
|
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.
|
J Clin Oncol
|
2009
|
4.20
|
|
10
|
Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.
|
Blood
|
2010
|
4.00
|
|
11
|
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
|
Blood
|
2006
|
3.91
|
|
12
|
Germline genomic variants associated with childhood acute lymphoblastic leukemia.
|
Nat Genet
|
2009
|
3.71
|
|
13
|
Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
|
Blood
|
2010
|
3.66
|
|
14
|
The genomic landscape of hypodiploid acute lymphoblastic leukemia.
|
Nat Genet
|
2013
|
3.43
|
|
15
|
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2011
|
3.40
|
|
16
|
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.
|
Blood
|
2009
|
3.02
|
|
17
|
Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.
|
Blood
|
2009
|
2.86
|
|
18
|
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
|
JAMA
|
2009
|
2.72
|
|
19
|
Outcomes after induction failure in childhood acute lymphoblastic leukemia.
|
N Engl J Med
|
2012
|
2.60
|
|
20
|
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected].
|
J Clin Oncol
|
2008
|
2.51
|
|
21
|
Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
|
Lancet Oncol
|
2012
|
2.46
|
|
22
|
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.
|
Nat Genet
|
2013
|
2.38
|
|
23
|
Acute Lymphoblastic Leukemia in Children.
|
N Engl J Med
|
2015
|
2.33
|
|
24
|
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
|
Blood
|
2012
|
2.09
|
|
25
|
Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient.
|
Pediatr Transplant
|
2004
|
2.04
|
|
26
|
Clinical application of asparaginase activity levels following treatment with pegaspargase.
|
Pediatr Blood Cancer
|
2014
|
1.99
|
|
27
|
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.
|
Blood
|
2012
|
1.90
|
|
28
|
Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
|
J Clin Oncol
|
2008
|
1.83
|
|
29
|
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.
|
J Natl Cancer Inst
|
2013
|
1.81
|
|
30
|
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
|
Clin Cancer Res
|
2007
|
1.80
|
|
31
|
Translocation (11;15;19): a highly specific chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients.
|
Am J Clin Oncol
|
2003
|
1.80
|
|
32
|
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia.
|
Blood
|
2008
|
1.79
|
|
33
|
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
|
Blood
|
2012
|
1.78
|
|
34
|
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.
|
Blood
|
2006
|
1.74
|
|
35
|
L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
|
Cancer
|
2010
|
1.69
|
|
36
|
Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.
|
Blood
|
2010
|
1.67
|
|
37
|
Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies.
|
Blood
|
2011
|
1.67
|
|
38
|
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.
|
Blood
|
2012
|
1.66
|
|
39
|
Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.
|
J Clin Oncol
|
2010
|
1.62
|
|
40
|
Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.
|
J Clin Oncol
|
2009
|
1.58
|
|
41
|
Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.
|
Blood
|
2012
|
1.47
|
|
42
|
The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia.
|
Blood
|
2011
|
1.45
|
|
43
|
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.
|
Nat Genet
|
2013
|
1.45
|
|
44
|
Inactivation of LEF1 in T-cell acute lymphoblastic leukemia.
|
Blood
|
2010
|
1.40
|
|
45
|
ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.
|
J Clin Oncol
|
2012
|
1.39
|
|
46
|
Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2011
|
1.39
|
|
47
|
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
|
Pediatr Blood Cancer
|
2011
|
1.33
|
|
48
|
Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B.
|
Blood
|
2012
|
1.29
|
|
49
|
Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.
|
Blood
|
2011
|
1.25
|
|
50
|
Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines.
|
Pediatr Blood Cancer
|
2008
|
1.23
|
|
51
|
Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
J Clin Oncol
|
2012
|
1.20
|
|
52
|
Genome-wide study of methotrexate clearance replicates SLCO1B1.
|
Blood
|
2012
|
1.17
|
|
53
|
Site-specific translocation and evidence of postnatal origin of the t(1;19) E2A-PBX1 fusion in childhood acute lymphoblastic leukemia.
|
Proc Natl Acad Sci U S A
|
2002
|
1.16
|
|
54
|
Identification of gene expression profiles that segregate patients with childhood leukemia.
|
Clin Cancer Res
|
2002
|
1.16
|
|
55
|
Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia.
|
J Clin Oncol
|
2010
|
1.14
|
|
56
|
Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.
|
Nat Rev Clin Oncol
|
2011
|
1.11
|
|
57
|
Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.
|
J Clin Oncol
|
2013
|
1.07
|
|
58
|
Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group.
|
Blood
|
2010
|
1.00
|
|
59
|
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.
|
Blood
|
2013
|
0.99
|
|
60
|
Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.
|
Blood
|
2013
|
0.99
|
|
61
|
Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031.
|
Clin Cancer Res
|
2012
|
0.98
|
|
62
|
Predicting relapse risk in childhood acute lymphoblastic leukaemia.
|
Br J Haematol
|
2013
|
0.98
|
|
63
|
Childhood leukemia--new advances and challenges.
|
N Engl J Med
|
2004
|
0.96
|
|
64
|
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
|
Blood
|
2013
|
0.95
|
|
65
|
Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.
|
J Clin Oncol
|
2008
|
0.93
|
|
66
|
A prospective study of anxiety, depression, and behavioral changes in the first year after a diagnosis of childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Cancer
|
2014
|
0.92
|
|
67
|
Acute leukemia in adolescents and young adults.
|
Semin Oncol
|
2009
|
0.91
|
|
68
|
Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study.
|
Mol Cancer
|
2010
|
0.89
|
|
69
|
Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.
|
Pediatr Blood Cancer
|
2010
|
0.89
|
|
70
|
E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features.
|
Br J Haematol
|
2003
|
0.88
|
|
71
|
ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A-HLF expression.
|
Pediatr Blood Cancer
|
2006
|
0.88
|
|
72
|
Mass spectrometric quantification of asparagine synthetase in circulating leukemia cells from acute lymphoblastic leukemia patients.
|
J Proteomics
|
2007
|
0.88
|
|
73
|
A new system identification approach to identify genetic variants in sequencing studies for a binary phenotype.
|
Hum Hered
|
2014
|
0.87
|
|
74
|
Novel targeted drug therapies for the treatment of childhood acute leukemia.
|
Expert Rev Hematol
|
2009
|
0.85
|
|
75
|
Family life events in the first year of acute lymphoblastic leukemia therapy: a children's oncology group report.
|
Pediatr Blood Cancer
|
2014
|
0.85
|
|
76
|
Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.
|
J Clin Oncol
|
2009
|
0.84
|
|
77
|
Pediatric acute lymphoblastic leukemia with a t(8;14)(q11.2;q32): B-cell disease with a high proportion of Down syndrome: a Children's Oncology Group study.
|
Cancer Genet
|
2012
|
0.83
|
|
78
|
Polycythemia vera in a child following treatment for acute lymphoblastic leukemia.
|
J Pediatr Hematol Oncol
|
2004
|
0.83
|
|
79
|
The controversy of varicella vaccination in children with acute lymphoblastic leukemia.
|
Pediatr Blood Cancer
|
2010
|
0.82
|
|
80
|
Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
|
Ann N Y Acad Sci
|
2014
|
0.82
|
|
81
|
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.
|
Pediatr Blood Cancer
|
2010
|
0.82
|
|
82
|
Recent advances in the understanding and treatment of pediatric leukemias.
|
Adv Pediatr
|
2012
|
0.81
|
|
83
|
Flavopiridol displays preclinical activity in acute lymphoblastic leukemia.
|
Pediatr Blood Cancer
|
2008
|
0.81
|
|
84
|
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.
|
Pediatr Blood Cancer
|
2012
|
0.81
|
|
85
|
Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).
|
Pediatr Blood Cancer
|
2014
|
0.80
|
|
86
|
Expression of CD44, but not CD44v6, predicts relapse in children with B cell progenitor acute lymphoblastic leukemia lacking adverse or favorable genetics.
|
Leuk Lymphoma
|
2008
|
0.80
|
|
87
|
Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children's Cancer Group.
|
J Pediatr Hematol Oncol
|
2003
|
0.79
|
|
88
|
Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma.
|
Am J Clin Pathol
|
2004
|
0.78
|
|
89
|
Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2014
|
0.78
|
|
90
|
Therapy of pediatric ALL: from Bowie to Obama.
|
Blood
|
2013
|
0.78
|
|
91
|
Acute tumor lysis syndrome in a 7-month-old with hepatoblastoma.
|
Curr Opin Pediatr
|
2010
|
0.77
|
|
92
|
Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study.
|
Br J Haematol
|
2012
|
0.77
|
|
93
|
Long-term disease control of refractory anaplastic large cell lymphoma with vinblastine.
|
J Pediatr Hematol Oncol
|
2009
|
0.76
|
|
94
|
Pediatric T-cell post-transplant lymphoproliferative disorder after solid organ transplantation.
|
Pediatr Blood Cancer
|
2008
|
0.76
|
|
95
|
Leukemic blasts with the paroxysmal nocturnal hemoglobinuria phenotype in children with acute lymphoblastic leukemia.
|
Am J Pathol
|
2012
|
0.76
|
|
96
|
Low-molecular-weight heparin use in a case of noncardiogenic multifocal perinatal thromboembolic stroke.
|
Adv Hematol
|
2009
|
0.75
|
|
97
|
BAC to the future? comparative genomic hybridization and genotyping pediatric leukemia cytogenetic abnormalities.
|
Pediatr Blood Cancer
|
2008
|
0.75
|
|
98
|
A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.
|
J Pediatr Hematol Oncol
|
2016
|
0.75
|
|
99
|
Therapies on the horizon for childhood acute lymphoblastic leukemia.
|
Curr Opin Pediatr
|
2016
|
0.75
|
|
100
|
Blood consult: therapeutic strategy and complications in the adolescent and young adult with acute lymphoblastic leukemia.
|
Blood
|
2012
|
0.75
|
|
101
|
Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.
|
Nature
|
2016
|
0.75
|
|
102
|
Metastatic alveolar rhabdomyosarcoma in multiple endocrine neoplasia type 2A.
|
Pediatr Blood Cancer
|
2010
|
0.75
|
|
103
|
Resolution of ambiguous low-level positive quantitative polymerase chain reaction results in TEL-AML1 positive ALL using a post-PCR fluorescent oligoligation method.
|
Br J Haematol
|
2006
|
0.75
|
|
104
|
Introduction and overview to issue on new developments in pediatric hematology/oncology.
|
Curr Opin Pediatr
|
2013
|
0.75
|
|
105
|
Children are not large mice.
|
Eur J Haematol
|
2013
|
0.75
|
|
106
|
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Crisis.
|
J Pediatr Hematol Oncol
|
2016
|
0.75
|
|
107
|
Native kidney post-transplant lymphoproliferative disorder in a non-renal transplant patient.
|
Pediatr Transplant
|
2008
|
0.75
|